Pharma channel feed

Safe­ty, ef­fi­ca­cy and dos­ing ques­tions linger for Lil­ly's Alzheimer's drug ahead of Mon­day ad­comm

Last year
FDA+

Nine years and four gener­ics lat­er, the HIV drug at the cen­ter of the Shkre­li con­tro­ver­sy still has a high price

Last year

Ab­b­Vie gets first taste of Ela­here po­ten­tial with new mid-stage win

Last year
R&D

J&J’s deal­mak­er: Plen­ty of ‘fire­pow­er,’ but most­ly fo­cused on tuck-in M&A

Last year
Deals

Lil­ly ex­ec says de­vel­op­ing new ther­a­pies for lu­pus is 'in scope'

Last year
R&D

Sen­ate Fi­nance Chair press­es HHS to crack down on cy­ber­se­cu­ri­ty in wake of Unit­ed­Health at­tack

Last year
FDA+
Health Tech

Ore­gon ju­ry says J&J owes talc claimant $260M

Last year
Law

Lykos’ MD­MA-as­sist­ed ther­a­py stum­bles at ad­comm amid ques­tions about study, safe­ty and abuse

Last year
FDA+

House law­mak­ers float trans­paren­cy re­forms for 340B pro­gram at hear­ing

Last year
FDA+

UK's NICE rec­om­mends Lil­ly's Zep­bound for weight loss

Last year

No­vo Hold­ings’ head of Asia on in­vest­ing in ‘Chi­na for Chi­na,’ and stay­ing out of biotech (for now)

Last year
Financing
China

Sanofi touts Phase 3 Sar­clisa da­ta in mul­ti­ple myelo­ma as it plays catch-up with J&J’s Darza­lex

Last year
R&D

At AS­CO: big read­outs, rev­enue ques­tions, and the ups and downs of AD­Cs

Last year
R&D

Fau­ci push­es back on pan­dem­ic crit­i­cisms be­fore di­vid­ed House pan­el

Last year
FDA+
Coronavirus

Agios plans tha­lassemia fil­ing in US af­ter un­veil­ing da­ta in trans­fu­sion-de­pen­dent pa­tients

Last year
FDA+

Delaware court lets Zan­tac law­suits go ahead, wip­ing $8B+ from GSK mar­ket cap

Last year
Law

Ex­clu­sive: Iso­tope short­age forces pause of Bris­tol My­ers Phase 3 ra­dio­phar­ma­ceu­ti­cal tri­al

Last year
R&D
Manufacturing

Up­dat­ed: With a promis­ing new Keytru­da con­tender, Sum­mit pre­pares to spar with Mer­ck

Last year
R&D
China

GSK plots Blenrep’s re­turn with more da­ta on its ADC for mul­ti­ple myelo­ma

Last year
R&D

Mer­ck CEO says Keytru­da is ‘not a re­peat­able mod­el’

Last year

FDA ques­tions da­ta on MD­MA-based ther­a­py in PTSD ahead of ad­vi­so­ry com­mit­tee

Last year
FDA+

No­var­tis sues Mary­land over state law ban­ning lim­its on dis­counts to 340B con­tract phar­ma­cies

Last year
Law

CHMP rec­om­mends 14 new ap­provals, sev­en la­bel ex­pan­sions

Last year
FDA+

Drug­mak­ers to Mary­land af­ford­abil­i­ty board: Cap­ping list prices may not help pa­tients

Last year
Law
First page Previous page 52535455565758 Next page Last page
A service from the Financial Times